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There is a consensus that Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) originated naturally from Bat coronaviruses (CoVs), in particular RaTG13. 
However, the SARS-CoV-2 host tropism/adaptation pattern has significant discrepancies 
compared to other CoVs, raising questions concerning the proximal origin of SARS-
CoV-2. The flat and non-sunken surface of the sialic acid-binding domain of SARS-
CoV-2 spike protein (S protein) conflicts with the general adaptation and survival pattern 
observed for all other CoVs. Unlike RaTG13, SARS-CoV-2 recombination presumably 
occurred between the S1/S2 domains of S protein enabling host furin protease utilization. 
Although millions of recorded cases have been recorded globally, SARS-CoV-2 S 
protein does not have any apparent further recombination, placing it in conflict with the 
recombination models of other CoVs.  Similarly, the S protein receptor-binding domain 
(RBD) of SARS-CoV-2 has not accumulated high-frequency non-synonymous 
substitutions, differentiating SARS-CoV-2 from other CoVs that have positive 




Andersen and colleagues documented the possible natural origin of SARS-CoV-2 from 
BatCoV RaTG13 1,2.  SARS-CoV-2 is the seventh zoonotic CoV virus capable of 
infecting humans, but the first and only human coronavirus (HCoV) with pandemic 
potential 3. Bat or rodent CoVs demonstrate certain specific changes in the S protein 
receptor-binding domain (RBD), as well as the S protein glycan-binding N-terminal 
 











domain (NTD), during host tropism/adaptation 4,5. SARS-CoV-2, unlike other CoVs, 
does not have those signature changes, suggesting that these RBD and NTD subdomains 
are of very recent origin. 
 
The "Canyon Hypothesis" explains the development of canyons, depression zones or 
cavities on the surfaces of influenza virus, human rhinovirus, and Meningo viruses 6. In 
CoVs (except SARS-CoV-2), the S protein NTD domain has several predicted glycan-
binding domains, with a common feature being the hidden localization of these glycan 
binding domains to cavities to limit their access to antibodies and immune cells 5. This 
pattern of CoVs is thought to be an evolutionary measure to restrict the recognition of 
these active sites by host immune system 4.  
  
HCoVs can evade detection by host glycan-binding immune receptors. Comparative 
genomic analysis of six HCoVs with their corresponding native bat or rodent CoVs 
suggests compatibility with the "Canyon Hypothesis" resulting from various adaptive S 
protein NTD non-synonymous mutations near or at the glycan binding domain which are 
predicted to result in these NTD domains being hidden below the protein surface5. The 
predicted flat, non-sunken pattern of the SARS-CoV-2 S protein NTD glycan binding 
domains conflicts with this evolutionary host tropism/adaptation strategy 7. 
 
A template-switching mechanism is presumably responsible for the high rate of RNA 
recombination in CoVs. In host cells, CoV RNAs show discontinuous RNA synthesis 
materialized by pauses of the RNA-dependent complex and subsequent jumps to 
downstream template acceptor sequences. This process results in subgenomic minus 
strand RNAs which serve as templates for subgenomic mRNAs. Due to the mechanistic 
similarity to recombination, this process might be at the origin of recombinant CoVs co-
opting other CoV or even host related sequences8. Instances include the mouse hepatitis 
coronavirus S protein NTD sialic acid binding domain, likely arising from recombination 
of viral RNA with human galectin RNA sequences 8.  
 












The furin recognition motif present at the SARS-CoV2 S1/S2 junction has no analogy in 
other "linage B" beta-coronaviruses, including neither pangolin-CoV nor RaTG13 1.  
This indicates that the S protein S1/S2 junction is not a hot spot for RNA recombination 
termination that depends on a pattern swapping templates (copy-choice) 8.  Additionally, 
clinical isolates of SARS-CoV-2 S protein have not indicated any further recombination 
in this S1/S2 area, suggesting that the addition of a motif for S1/S2 site furin cleavage 
constituted a unique recombination occurrence. Finally, the CoV-unique insertion of 4 
amino-acids creating a novel RRAR furin cleavage site introduces two arginine codons 
CGG-CGG, whose usage is extremely rare in CoVs, further supporting the hypothesis of 
a unique recombination occurrence. 
 
HCoVs have high-frequency “hot spots” for non-synonymous amino acid replacements 
that can possibly create  positive selection for host tropism/adaptation, resistance to 
neutralizing antibodies, or immune evasion 2. Interestingly, clinical SARS-CoV-2 
isolates to date have only a single high frequency non-synonymous mutation, D614G, in 
their S protein 9. Based on currently known mutation rates and patterns in clinical isolates 
of SARS-CoV-2, the S protein does not appear to be a mutational “hot spot” for SARS-
CoV-2, unlike other human CoVs.  
 
SARS-CoV-2 is the seventh HCoV, but the first HCoV with pandemic potential. SARS-
CoV disappeared without a pandemic, and MERS-CoV is mostly endemic to the Arabian 
Peninsula with some additional limited traveler infections resulting in outbreaks in South 
Korea 3,4. These unique features of SARS-CoV-2 raise several questions concerning the 
proximal origin of the virus that require further discussion.  
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